Business Context and Reporting Period
The submitted filing is NeuroBo Pharmaceuticals, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2023. The request metadata identifies the company as Metavia Inc., which does not match the registrant named in the filing.
NeuroBo is a clinical-stage biotechnology company focused primarily on cardiometabolic diseases. Its lead programs are DA-1241 for NASH and type 2 diabetes and DA-1726 for obesity and potentially NASH. The company has no commercial products and has not generated product revenue.
Key Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue reported |
| Research and development expense | $0.637 million | $0.920 million | Down $0.283 million |
| General and administrative expense | $1.883 million | $1.955 million | Down $0.072 million |
| Total operating expenses | $2.520 million | $2.875 million | Down $0.355 million |
| Net loss | $2.604 million | $2.875 million | Improved by $0.271 million |
| Basic and diluted loss per share | $0.06 loss | $3.24 loss | Improved |
| Net cash used in operating activities | $2.547 million | $4.829 million | Usage decreased $2.282 million |
| Cash at March 31 | $30.813 million | $11.557 million | Higher year over year |
There was no income tax provision or benefit. The filing does not provide a meaningful operating margin because the company reported no revenue. No conventional interest-bearing debt is reported; current liabilities included $9.444 million of warrant liabilities, $1.119 million of accounts payable, and $0.417 million of accrued liabilities.
Total assets were $31.488 million at March 31, 2023, compared with $33.534 million at December 31, 2022. Stockholders’ equity was $20.508 million, down from $21.750 million. The accumulated deficit was $98.399 million.
Material Changes Versus the Prior Comparable Period
- R&D expense declined primarily because of reduced clinical trial activity and drug manufacturing costs related to completion of the ANA001 trial, partly offset by DA-1241 IND-related fees and DA-1241 and DA-1726 research activities.
- G&A expense declined modestly due to lower insurance and stock-based compensation costs, partly offset by higher legal, professional, payroll, and executive consulting costs.
- Operating cash use improved substantially, mainly because Q1 2022 included larger working-capital cash usage.
- The company issued 1,740,666 common shares through warrant exercises during the quarter, increasing shares outstanding from 25.436 million at December 31, 2022 to 27.177 million at March 31, 2023.
- Warrant liabilities declined from $10.796 million to $9.444 million, including a $1.436 million reclassification upon warrant exercises. A $0.084 million loss resulted from the change in fair value.
- Outstanding warrants decreased from 15.264 million to 13.524 million, principally from cashless exercises of Series A and Series B warrants.
Guidance, Outlook, Risks, and Unusual Items
- The FDA cleared the DA-1241 IND in May 2023, after the reporting period. Management planned to initiate a Phase 2a NASH study in the third quarter of 2023. The planned study includes up to 98 subjects across two parts and evaluates DA-1241 alone and in combination with sitagliptin.
- Management intended to file an IND for DA-1726 and begin Phase 1 clinical trials in the second half of 2023.
- The company expected its $30.8 million of cash to fund operations into 2024 and for at least 12 months from issuance of the financial statements, but stated that additional funding will be required before sustainable revenue or profitability. Potential future financing may include equity or debt, with no assurance of availability or terms.
- The company expects continued significant operating expenses, particularly for clinical development, preclinical studies, manufacturing, regulatory activities, intellectual property, and potential commercialization infrastructure.
- Material risks include clinical-trial failure, inability to obtain regulatory approvals, delays in enrollment or manufacturing, inability to raise capital, dependence on third parties, market acceptance, stock-price effects on financing and license arrangements, and the possibility that the company never becomes profitable.
- The Dong-A license includes potential regulatory milestone payments of up to $178 million for DA-1726 and $138 million for DA-1241, commercial milestones, and single-digit royalties on net sales. No related milestone or royalty liability was accrued because achievement was not considered probable.
- Legacy agreements contain additional potential milestone, royalty, and contingent value payments, including obligations related to Niclosamide products and Gemcabene. No related liabilities were recorded because the required events were uncertain.
- Disclosure controls and procedures were not effective at March 31, 2023 because previously identified material weaknesses remained outstanding, including insufficient segregation of duties, excessive system access, and inadequate supervision and review over financial reporting.
- After March 31, 2023, an additional 65,000 Series B warrants were exchanged for common shares.
Investor Verification Items
- Verify the registrant identity: the filing is for NeuroBo Pharmaceuticals, Inc., not Metavia Inc.
- Confirm the FDA clearance and actual initiation, enrollment, costs, and clinical milestones for the DA-1241 Phase 2a program.
- Assess cash runway against planned DA-1241 and DA-1726 development spending and determine the timing, structure, and dilution risk of future financing.
- Review the terms, exercise activity, fair-value methodology, and potential dilution from the remaining 13.524 million warrants and outstanding stock options.
- Monitor remediation of the material weaknesses in internal control over financial reporting.
- Evaluate the probability and potential financial impact of Dong-A, legacy license, milestone, royalty, and contingent value obligations.